Clearance Summary
IBL C1Q-CIC CIA TEST received FDA 510(k) clearance under submission number K032254, sponsored by Ibl GmbH. The device was reviewed via the Traditional premarket notification pathway and assigned to the Immunology review panel. The statutory decision date of record is 2003-08-29.
- Submission: K032254
- Applicant / Sponsor: Ibl GmbH
- Clearance pathway: Traditional
- Review panel: Immunology
- Device class: Class II
- Regulation citation: 21 CFR 866.5240
- Decision date: 2003-08-29
Classification & Regulation
This clearance is catalogued under FDA product code DAK and 21 CFR 866.5240, within the Immunology review panel as a Class II device.